MedPath

Effect of combination of calcium channel blocking drugs and iron lowering drugs on iron levels in patients with thalassemia major (blood disorder requiring repeated blood transfusions).

Not Applicable
Conditions
Health Condition 1: D561- Beta thalassemia
Registration Number
CTRI/2019/06/019787
Lead Sponsor
Department of Pediatrics
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1. Patients with serum ferritin >1000 ng/ml

2. Received >10 blood transfusions

3. Patients on stable iron chelation for >6 months

Exclusion Criteria

1. Patients with congenital or acquired heart disease

2. Patients with significant renal disease (serum creatinine >3 times normal or eGFR <30 ml/min/m2)

3. Patients with significant liver disease (ALT/AST >3 times normal)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percent change in myocardial iron concentrationTimepoint: 0, 6, 12 months
Secondary Outcome Measures
NameTimeMethod
Percent change in liver iron concentration <br/ ><br>Percent change in serum ferritin value <br/ ><br>Change in LVEF at 12 monthsTimepoint: 0, 6, 12 months
© Copyright 2025. All Rights Reserved by MedPath